Feature | September 13, 2013| Dave Fornell

Vascular Closure Devices Aid Closure of Large Access Sites

Off-label use of closure devices speeds hemostasis following TEVAR, TAVR and pVAD use

There is no shortage of debate among interventional cardiologists over whether vascular closure devices should be used for standard cath lab procedures. However, some say these devices have a definite niche in areas where they were not originally intended but have found frequent off-label use because of their utility. 

The larger sizes of devices used for transcatheter endovascular aortic repair (TEVAR) and transcatheter aortic valve replacement (TAVR) requires a much larger arteriotomy site than standard percutaneous coronary interventions (PCI). However, these larger holes also make it more difficult to achieve hemostasis using manual compression alone. 

Some of these devices are as large as 24 French, and anything larger requires a surgical cut-down, said Chris Malaisrie, M.D., assistant professor of surgery, division of cardiac surgery, Northwestern University Memorial Hospital, Chicago. “You can’t just hold pressure on a hole that size,” Malaisrie explained. “I use the preclose technique for large bore access for TEVAR and TAVI. I currently use Abbott Prostar or Abbott Perclose Proglide off-label. I prefer the ProGlide, even though you need two of them to close.”

The Abbott Perclose ProGlide suture-mediated closure system provides a suture for vascular closure of 5 – 21 French femoral artery access sites. The vendor says for sheath sizes greater than 8 French, at least two devices and the pre-close technique are required. The system helps reduce time to hemostasis, ambulation and discharge. 

Another off-label application of these devices has been found when using percutaneous ventricular assist devices (pVADs), such as the Abiomed Impella or the CardiacAssist TandemHeart systems. The TandemHeart system uses cannula sizes up to 17 French. 

“We primarily use two ProGlides for Impella 13 French closure using an off-label pre close technique,” said Mladen Vidovich, M.D., FACC, FSCAI, chief, section of cardiology, Jesse Brown VA Medical Center, and associate professor of medicine, University of Illinois, Chicago. 

He said cath labs at both Jesse Brown VA and UIC used closure devices on a regular basis for femoral access PCI in the past to speed patient ambulation and cut nursing time. However, he said both facilities have drastically reduced the need for these devices. 

“Due to our high radial access volume, our closure device use has dwindled, but for the rare groin I’ll use Proglide,” Vidovich said.   

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Overlay Init